Shenzhen Chipscreen Biosciences Co (688321) - Net Assets

Latest as of September 2025: CN¥1.66 Billion CNY ≈ $242.31 Million USD

Based on the latest financial reports, Shenzhen Chipscreen Biosciences Co (688321) has net assets worth CN¥1.66 Billion CNY (≈ $242.31 Million USD) as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥3.63 Billion ≈ $531.65 Million USD) and total liabilities (CN¥1.98 Billion ≈ $289.34 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Shenzhen Chipscreen Biosciences Co liquid asset ratio to evaluate the company's liquid asset resilience ratio.

Key Net Assets Metrics

Metric	Value
Current Net Assets	CN¥1.66 Billion
% of Total Assets	45.58%
Annual Growth Rate	28.45%
5-Year Change	5.84%
10-Year Change	N/A
Growth Volatility	71.01

Shenzhen Chipscreen Biosciences Co - Net Assets Trend (2016–2024)

This chart illustrates how Shenzhen Chipscreen Biosciences Co's net assets have evolved over time, based on quarterly financial data. Also explore 688321 current and non-current assets for the complete picture of this company's asset base.

Annual Net Assets for Shenzhen Chipscreen Biosciences Co (2016–2024)

The table below shows the annual net assets of Shenzhen Chipscreen Biosciences Co from 2016 to 2024. For live valuation and market cap data, see Shenzhen Chipscreen Biosciences Co market capitalisation.

Year	Net Assets	Change
2024-12-31	CN¥1.58 Billion ≈ $231.36 Million	-7.53%
2023-12-31	CN¥1.71 Billion ≈ $250.21 Million	+8.52%
2022-12-31	CN¥1.58 Billion ≈ $230.57 Million	+11.15%
2021-12-31	CN¥1.42 Billion ≈ $207.44 Million	-5.10%
2020-12-31	CN¥1.49 Billion ≈ $218.59 Million	+3.28%
2019-12-31	CN¥1.45 Billion ≈ $211.64 Million	+203.28%
2018-12-31	CN¥476.90 Million ≈ $69.79 Million	+5.85%
2017-12-31	CN¥450.55 Million ≈ $65.93 Million	+111.13%
2016-12-31	CN¥213.40 Million ≈ $31.23 Million	--

Equity Component Analysis

This analysis shows how different components contribute to Shenzhen Chipscreen Biosciences Co's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

Retained earnings have grown by 10806100360.0% over the analyzed period, indicating profitable operations and earnings retention.

Current Equity Component Breakdown (December 2024)

Component	Amount	Percentage
Retained Earnings	CN¥3.01 Million	0.19%
Common Stock	CN¥407.80 Million	25.79%
Other Comprehensive Income	CN¥131.84 Million	8.34%
Other Components	CN¥1.04 Billion	65.68%
Total Equity	CN¥1.58 Billion	100.00%

Shenzhen Chipscreen Biosciences Co Competitors by Market Cap

The table below lists competitors of Shenzhen Chipscreen Biosciences Co ranked by their market capitalization.

Company	Market Cap
BigBearai Holdings Inc NYSE:BBAI	$1.87 Billion
United Parks & Resorts Inc NYSE:PRKS	$1.87 Billion
Chalet Hotels Limited NSE:CHALET	$1.87 Billion
Shandong Yisheng Livestock & Poultry Breeding Co Ltd SHE:002458	$1.87 Billion
Metro Investment Development Co Ltd SHG:600683	$1.87 Billion
Surgery Partners Inc NASDAQ:SGRY	$1.87 Billion
Silicon2 Co. Ltd. KQ:257720	$1.87 Billion
Marriot Vacations Worldwide NYSE:VAC	$1.87 Billion

Equity Growth Attribution

This analysis shows how different factors contributed to changes in Shenzhen Chipscreen Biosciences Co's equity between the two most recent reporting periods.

Equity Growth Insights

From 2023 to 2024, total equity changed from 1,586,125,125 to 1,581,098,748, a change of -5,026,377 (-0.3%).
Net loss of 114,570,598 reduced equity.
Dividend payments of 27,628,241 reduced retained earnings.
Share repurchases of 15,000,000 reduced equity.
Other comprehensive income increased equity by 78,373,504.
Other factors increased equity by 73,798,958.

Equity Change Factors (2023 to 2024)

Factor	Impact	Contribution
Net Income	CN¥-114.57 Million	-7.25%
Dividends Paid	CN¥27.63 Million	-1.75%
Share Repurchases	CN¥15.00 Million	-0.95%
Other Comprehensive Income	CN¥78.37 Million	+4.96%
Other Changes	CN¥73.80 Million	+4.67%
Total Change	CN¥-	-0.32%

Book Value vs Market Value Analysis

This analysis compares Shenzhen Chipscreen Biosciences Co's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

Current price-to-book ratio: 8.08x
The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
The price-to-book ratio has decreased from 48.38x to 8.08x over the analyzed period, indicating reduced market premium.

Historical Price-to-Book Ratios

Date	Book Value per Share	Market Price	P/B Ratio
2016-12-31	CN¥0.65	CN¥31.30	x
2017-12-31	CN¥1.29	CN¥31.30	x
2018-12-31	CN¥1.33	CN¥31.30	x
2019-12-31	CN¥3.53	CN¥31.30	x
2020-12-31	CN¥3.64	CN¥31.30	x
2021-12-31	CN¥3.46	CN¥31.30	x
2022-12-31	CN¥3.72	CN¥31.30	x
2023-12-31	CN¥3.89	CN¥31.30	x
2024-12-31	CN¥3.88	CN¥31.30	x

Capital Efficiency Dashboard

This dashboard shows how efficiently Shenzhen Chipscreen Biosciences Co utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

Current Return on Equity (ROE): -7.25%
The company may be facing challenges in efficiently utilizing shareholder equity.
DuPont Analysis Breakdown:
• Net Profit Margin: -17.41%
• Asset Turnover: 0.20x
• Equity Multiplier: 2.06x
Recent ROE (-7.25%) is below the historical average (2.09%), suggesting potential challenges in capital efficiency.

Historical Capital Efficiency Metrics

Year	Return on Equity	Net Profit Margin	Asset Turnover	Equity Multiplier	Economic Value Added
2016	2.46%	6.14%	0.21x	1.89x	CN¥-16.10 Million
2017	5.34%	21.79%	0.17x	1.46x	CN¥-20.98 Million
2018	6.53%	21.10%	0.21x	1.50x	CN¥-16.52 Million
2019	1.34%	11.17%	0.10x	1.17x	CN¥-125.21 Million
2020	2.08%	11.52%	0.16x	1.16x	CN¥-118.34 Million
2021	1.55%	5.10%	0.23x	1.34x	CN¥-119.80 Million
2022	1.15%	3.30%	0.18x	1.91x	CN¥-134.06 Million
2023	5.60%	16.96%	0.16x	2.02x	CN¥-69.77 Million
2024	-7.25%	-17.41%	0.20x	2.06x	CN¥-272.68 Million

Industry Comparison

This section compares Shenzhen Chipscreen Biosciences Co's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.

Industry Context

Industry: Drug Manufacturers - Specialty & Generic
Average net assets among peers: $5,514,568,242
Average return on equity (ROE) among peers: 7.73%

Peer Company Comparison

Company	Net Assets	Return on Equity	Debt-to-Equity	Market Cap
Shenzhen Chipscreen Biosciences Co (688321)	CN¥1.66 Billion	2.46%	1.19x	$1.87 Billion
Shenzhen Neptunus Bioengineering Co Ltd (000078)	$52.15 Million	21.80%	0.58x	$1.05 Billion
Anhui Fengyuan Pharmaceutical Co Ltd (000153)	$1.15 Billion	3.98%	1.16x	$438.59 Million
Shan Dong Dong-E E-Jiao Co Ltd (000423)	$10.00 Billion	4.41%	0.16x	$5.06 Billion
Livzon Pharmaceutical Group Inc (000513)	$1.04 Billion	4.86%	0.62x	$2.76 Billion
Wedge Industrial Co Ltd (000534)	$1.15 Billion	11.42%	1.59x	$2.94 Billion
Yunnan Baiyao Group Co Ltd (000538)	$38.10 Billion	10.98%	0.30x	$13.74 Billion
Hainan Haiyao Co Ltd (000566)	$2.20 Billion	-4.84%	2.35x	$958.72 Million
Tus Pharmaceutical Group Co Ltd (000590)	$579.72 Million	-6.59%	0.41x	$386.52 Million
Northeast Pharmaceutical Group Co Ltd (000597)	$775.11 Million	6.08%	2.16x	$1.04 Billion
Jilin Aodong Pharmaceutical Group Co Ltd (000623)	$103.02 Million	25.18%	1.40x	$3.29 Billion

About Shenzhen Chipscreen Biosciences Co

SHG:688321 China Drug Manufacturers - Specialty & Generic

Market Cap

$1.87 Billion

CN¥12.76 Billion CNY

Market Cap Rank

#6578 Global

#1529 in China

Share Price

CN¥31.30

Change (1 day)

-2.34%

52-Week Range

CN¥17.12 - CN¥42.97

All Time High

CN¥102.00